Donation after brain death followed by circulatory death, a novel donation pattern, confers comparable renal allograft outcomes with donation after brain death

Qipeng Sun1†, Honglan Zhou2†, Ronghua Cao3, Minzhuang Lin4, Xuefeng Hua1, Liangqing Hong1, Zhengyu Huang1, Ning Na1, Ruiming Cai4, Gang Wang2, Fanhang Meng3 and Qiquan Sun1*

Abstract

Background: Organ donation after brain death (DBD) is the standard strategy for organ transplantation; however, the concept of brain death is not universally accepted due to cultural beliefs and barriers amongst billions of people worldwide. Hence, a novel donation pattern has been established in China which outlines the concept of donation after brain death followed by circulatory death (DBCD). Differently from any current donation classification, this new concept is formulated based on combination of recognizing brain death and circulatory death. Should approval be gained for this definition and approach, DBCD will pave a novel donation option for billions of people who cannot accept DBD due to their cultural beliefs.

Methods: A multi-center, cohort study was conducted from February 2012 to December 2015. 523 kidney transplant recipients from four kidney transplant institutions were enrolled into the study, of which, 383 received kidneys from DBCD, and 140 from DBD. Graft and recipient survivals following transplantation were retrospectively analyzed. Postoperative complications including delayed graft function, and acute rejection, were also analyzed for both groups.

Results: DBCD could achieve comparable graft and recipient survivals in comparison with DBD (Log-rank P = 0.32 and 0.86, respectively). One-year graft and recipient survivals were equal between DBCD and DBD groups (97.4% versus 97.9%, P = 0.10; 98.4% versus 98.6%, P = 1.0, respectively). Furthermore, DBCD did not increase incidences of postoperative complications compared with DBD, including delayed graft function (19.3% versus 22.1%, P = 0.46) and acute rejection (9.1% versus 8.6%, P = 1.0). Additionally, antithymocyte globulin as induction therapy and shorter warm ischemia time decreased incidence of delayed graft function in DBCD group (16.8% on antithymocyte globulin versus 27.2% on basiliximab, P = 0.03; 16.7% on ≤18 min versus 26.7% on > 18 min group, P = 0.03).

Conclusions: Kidney donation through DBCD achieves equally successful outcomes as DBD, and could provide a feasible path to graft availability for billions of people who face barriers to organ donation from DBD.

Keywords: Donation after brain death followed by circulatory death, Donation after brain death, Delayed graft function, Acute rejection

© The Author(s). 2018. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

Kidney transplantation is currently the preferred treatment mode for patients with end-stage renal disease [1]. Although kidney donation after brain death (DBD) is considered the standard donation strategy and has been established in Western countries, there are many obstacles preventing acceptance of the Harvard criteria for brain death in some countries, such as China and Japan [2–6]. In many of these countries, such as Japan, living kidney donations from a relative often have to be used to relieve pressure placed on organ sources, but ethical and serious constraints cause controversy in these instances [2, 7]. Although donation after circulatory death (DCD) has the potential to increase kidney transplants, inferior long-term survival of recipients from DCD, and a higher incidence of delayed graft function (DGF) make clinicians reluctant to accept DCD transplantsations [8, 9]. Hence, establishing a novel donation path for these large populations unable to accept DBD is now critical.

In the light of cultural barriers, efforts to promote DBD in China have not been satisfied from 2009 [10]. Hence, a novel donation concept namely organ donation after brain death followed by circulatory death (DBCD) was officially initiated in 2011, which could be regarded as combination of recognizing brain death and circulatory death [11, 12]. These donors should first be declared as brain dead, and then processed with planned withdrawal of mechanical support, and subsequent execution of cardiac death protocols, which is totally different from the international common practice of Maastricht criteria of donation after cardiac death [11, 12]. Should approval be gained for this definition and approach, DBCD will pave a novel donation option for billions of people who cannot accept DBD due to their cultural beliefs. To this end, we conducted a multi-center cohort study to compare outcomes from kidney donation through DBCD compared with DBD.

**Methods**

**Study design**

This was a multi-center, retrospective, observational cohort study involving 523 kidney transplants from DBCD or DBD from February 2012 to December 2015. The transplants were performed in four institutions: The Third Affiliated Hospital of Sun Yat-sen University, The First Affiliated Hospital of Jilin University, The Second Affiliated Hospital of Guangzhou Traditional Chinese Medicine University, and The Third Affiliated Hospital of Guangzhou Medical University. Of the 523 kidney transplant recipients enrolled, 383 received DBCD and 140 DBD.

Donors were selected based on confirmed patient identity, age ≤ 65 years, no history of kidney disease, drug abuse or uncontrollable psychotic symptoms, no active infection including HIV, bacteria or fungus, no history of uncontrolled hypertension, diabetes mellitus with complications, no history of malignant melanoma, metastatic or incurable malignancy [11].

No organs from executed prisoners were used in the study, and procurement of kidneys from all donors was conducted in accordance with the Declaration of Helsinki and Istanbul Declaration, and approved by the Human Organ Transplantation and Ethics Committee of each institution. The donation types were determined by donors’ families, who also signed consent forms that were approved by the Ethics Committees of each institution. The Ethics Committees were established according to the Operational Guidelines for Ethics Committees that Review Biomedical Research developed by the World Health Organization, and consequently included physicians, lawyers, statisticians, paramedical personnel, and laypersons [13]. Organ allocation was conducted equitably and transparently by the China Organ Transplant Response System [3].

The definition of brain death was strictly determined by the exclusion of confounders, as well as the presence of three essential findings; namely, irreversible coma, absence of spontaneous motor activity, and the absence of all brain-stem reflexes. To determine the cessation of respiratory function, an apnea test should be carried out before declaration of brain death as follows: after mechanical ventilation and vasopressors withdrawn, 100% concentration of O2 with a velocity of 6 L/minute was added to patient via tracheal intubation for 8–10 min. Breathing movement should be closely observed and arterial blood gas analysis should be tested finally. The cessation of spontaneous respiratory function was defined as no breathing movement with PaCO2 equal or greater than 60 mmHg or a rise of 20 mmHg more than basal level. The brain death of each donor was adjudicated independently by two neurologists or neurosurgeons [5, 11].

Cardiac death was legally defined as irreversible cessation of circulatory function, based on definitive proof by confirmatory tests, such as electrocardiography, intra-arterial monitoring or Doppler ultrasound. An observation period of 5 min was also employed, to ensure the irreversibility and permanence of the patient’s cardiac death [11].

**Organ procurement and management**

Organ donation and recovery was conducted by organ procurement organization established by the National Health and Family Planning Commission of China. DBDs were procured after declaration of brain death according to the aforementioned diagnostic criteria. For DBCDs, following determination of brain death, written consent was obtained from the donor’s immediate family, agreeing to donation of the kidney and withdrawal of life support. The obtained consent for donation was then reported to the
Organ Donation Committee, which supervised the DBCD process.

Donors were monitored with invasive blood pressure sensors in the operating room. Following condolences, mechanical ventilation and vasopressors were withdrawn, and vital signs were continued to be monitored. The definition of cardiac death was determined according to the aforementioned criteria, and after 5 min of observation following cardiac arrest, death was declared and organ recovery initiated. According to the national guidelines in China, warm ischemia time was recorded from the termination of life support to the hypothermic perfusion of graft, and cold ischemia time was recorded as the duration from hypothermic perfusion to blood reperfusion during transplantation surgery. The warm ischemia time of the kidney grafts was limited to under 60 min [11]. Zero-time biopsies were also performed when deemed necessary. The protocol for DBCD in China was shown in Fig. 1.

Immunosuppressive regimen

Either anti-thymocyte globulin (ATG) or basiliximab was administered as induction therapy. Additionally, methylprednisolone (500 mg/day) was continuously administered intravenously during the first 3 days postoperatively. Maintenance immunosuppressive regimens consisted of a calcineurin inhibitor, mycophenolate mofetil, and prednisolone. Mycophenolate mofetil initiated immediately after transplantation was maintained at a daily dose of 1.0–1.5 g. Tacrolimus or cyclosporine was started on Day 2–4 at 0.1–0.15 mg/kg/day or 6–8 mg/kg/day, respectively, according to the level of recovery of renal graft function. The immunosuppressive regimens were adjusted to achieve target therapeutic trough levels in peripheral blood. Oral administration of prednisolone, initiated at 30 mg/day on Day 4 following transplantation, was reduced by 5 mg every week to a maintenance dose of 10–15 mg/day.

Postoperative complications

Postoperative complications such as incidences of DGF, primary non-function (PNF) and acute rejection (AR) were retrospectively analyzed in this study. The definition of DGF in our study is the use of dialysis in the first postoperative week, or failure of serum creatinine to decrease by 10% in the first 48 h following transplantation [14]. PNF was defined as failure of the transplanted

---

**Fig. 1** The protocol for organ DBCD in China
kidney function, and the need for dialysis therapy [15]. Recipients with primary non-function were excluded from delayed graft function defined as need for dialysis after transplantation. AR was identified upon analysis of a biopsy and classified according to the Banff 2013 classification [16]. Human leukocyte antigen (HLA) mismatching between donor and recipient was categorized according to differences at the HLA-A, HLA-B, and HLA-DR loci: 0–1 of six possible mismatches, 2–4 mismatches, and 5–6 mismatches [17]. Positive panel-reactive antibody (PRA) was defined as peak PRA more than 10% in our study, and a categorical variable for positive PRA was made as following: peak PRA 10–50%, 50–80%, and >80%. In addition to the above, other severe postoperative complications including complicated urinary tract infection, severe pneumonia, severe bleeding, anastomotic stenosis of the ureter/bladder, renal allograft rupture, lymphorrhagia and urine leakage were also analyzed retrospectively.

Follow-up after kidney transplantation from DBCD and DBD All recipients were followed up and routine tests as well as concentration of calcineurin inhibitors were regularly assessed. Graft and recipient survivals were also analyzed. Follow-up of a patient ceased upon the patient's death, PNF, resection of the transplanted kidney or secondary transplantation due to complications arising from the first.

Statistical analysis
Baseline characteristics of recipients and donors as well as postoperative complications between the two groups were compared using the t-test for continuous variables or the chi-squared test for discrete variables. Kaplan–Meier curves were plotted to depict graft and recipient survivals, and a curve comparison was performed between the two groups using the log-rank test. Incomplete data entries were not included in our analyses. Risk factors for survivals were studied using a cox regression regression analysis. All analyses were performed with Statistical Package for Social Science 22.0 for Windows (IBM Corp., Armonk, NY, USA). P values less than 0.05 were considered statistically significant.

Results
Baseline characteristics of donors and recipients
In this study, 199 DBCD and 85 DBD donors were included. There was no significant difference in gender, use of vasoactive drugs, cardio-pulmonary resuscitation, intensive care unit time, body mass index and serum terminal creatinine between the two groups (all P > 0.05) (Table 1). No significant difference was also found in prevalence of arterial hypertension, heart disease, or diabetes (all P > 0.05). Although no significant difference was found in mean age between two groups, 59.8% of DBCD donors were older than 40 years, compared with 12.1% of DBD donors (P < 0.05). A significant difference was found in the causes of death and a significantly greater proportion of DBD donors died from cerebral trauma than DBCD donors (69.4% versus 53.3%, P = 0.01). Likewise, a significantly greater proportion of DBCD donors died from cerebrovascular accident than DBD donors (42.2% versus 27.1%, P = 0.02). The warm ischemia time of DBCD donation was 16.2 ± 5.2 min, with a range of 9 to 35 min. Among different groups of warm ischemia time, 57.8% donors had warm ischemia time 10–20 min. No significant difference was found in cold ischemia time between the two groups (5.5 ± 2.2 in DBCD versus 5.7 ± 2.4 in DBD, P = 0.06).

No significant differences were found between recipients from the two groups for most baseline characteristics (P > 0.05) (Table 2). The majority of recipients received their first transplantations in this study. Panel-reactive antibody (PRA) was positive in 12 (3.1%) of recipients in the DBCD group, compared with five (3.6%) in the DBD group, although this was not statistically different (P = 0.78). All the positive PRA recipients in the two groups were classified into 10–50%. Regarding induction therapy, 291 recipients (76%) in the DBCD group received ATG compared with 39 recipients (27.9%) in the DBD group (P < 0.05).

### Table 1 Demographics of donors included in this study

| Clinical Values | DBCD (n = 199) | DBD (n = 85) | P |
|----------------|---------------|--------------|---|
| Age (years)    | 40.4 ± 13.0   | 28.8 ± 11.6  | 0.26 |
| Gender (%Female) | 15.1          | 15.3         | 1  |
| Cause of death, n (%) |              |              |    |
| Cerebral trauma | 106(53.3)     | 59(69.4)     | 0.04 |
| Cerebrovascular accident | 84(42.2) | 23(27.1) |   |
| Others         | 9(4.5)        | 3(3.5)       |   |
| Using of vasoactive drugs, n (%) | 153(76.9) | 71(83.5) | 0.27 |
| Cardio-pulmonary resuscitation, n (%) | 17(8.5) | 7(8.2) | 1.00 |
| ICU Time of Donor(days) | 6.8 ± 5.7 | 8.1 ± 6.7 | 0.14 |
| Donor BMI (kg/m²) | 22.9 ± 2.2 | 21.5 ± 3.6 | 0.11 |
| Terminal donor Cr(μmol/L) | 149.9 ± 55.9 | 147.4 ± 123.3 | 0.90 |
| History of arterial hypertension, n (%) | 43(21.6) | 11(12.9) | 0.10 |
| History of heart disease, n (%) | 6(3.0) | 5(5.9) | 0.31 |
| History of diabetes, n (%) | 6(3.0) | 1(1.2) | 0.68 |
| Cold ischemia time(hours) | 5.5 ± 2.2 | 5.7 ± 2.4 | 0.06 |
| Warm ischemia time(minutes) | 16.2 ± 5.2 | – | – |
| < 10 min | 39(19.6) | – | – |
| 10–20 min | 115(57.8) | – | – |
| 20–30 min | 37(18.6) | – | – |
| > 30 min | 8(4.0) | – | – |

*ICU* intensive care unit, *BMI* body mass index, *Cr* creatinine
Table 2 Demographics of recipients included in this study

| Clinical Values | DBCD (n = 383) | DBD (n = 140) | P       |
|-----------------|----------------|---------------|---------|
| Age (years)     | 42.5 ± 11.1    | 43.1 ± 11.6   | 0.85    |
| Gender (%female)| 37.6           | 32.1          | 0.26    |
| Preoperative Cr (μmol/L) | 931.2 ± 287.4  | 1033.6 ± 324  | 0.06    |
| Previous transplants, n (%) |                 |               |         |
| First transplant | 374(97.7)      | 135(96.4)     | 0.54    |
| Second transplant | 9(2.3)         | 5(3.6)        |         |
| PRA, n (%)      |                 |               |         |
| < 10%           | 371(96.9)      | 135(96.4)     | 0.78    |
| 10–50%          | 12(3.1)        | 5(3.6)        |         |
| Induction therapy, n (%) |             |               |         |
| antithymocyte globulin | 291(76)       | 39(27.9)      | 0       |
| basiliximab     | 92(24)         | 101(72.1)     |         |
| HLA mismatches, n (%) |             |               |         |
| 0–1             | 274(71.5)      | 106(75.7)     | 0.22    |
| 2–4             | 79(20.6)       | 29(20.7)      |         |
| 5–6             | 30(7.9)        | 5(3.6)        |         |

Cr creatinine, PRA panel-reactive antibody, HLA human leukocyte antigen

Postoperative complications
There was no significant difference in postoperative complications between the two groups (all P > 0.05; Table 3). Of the DBCD recipients, 19.3% developed DGF 1 week postoperatively, compared with 22.1% of DBD recipients (P = 0.46). Five recipients in DBCD group developed PNF, but none from DBD group (P = 0.33). However, all the five grafts with PNF were confirmed with severe glomerulosclerosis by zero-time biopsy. ATG was found to be related with lower incidence of DGF in comparison to basiliximab in the DBCD group (16.8% with DGF on ATG versus 27.2% with DGF on basiliximab, P = 0.03). Additionally, 9.1% cases from DBCD group suffered from AR compared with 8.6% in DBD group (P = 1.0). According to a previous published study, we divided warm ischemia time into two groups: ≤18 min and > 18 min [18]. Compared with the ≤18 min group, 54 donors (23.7%) had WIT > 18 min, of whom 17 (31.5%) had DGF. (31.5% versus 15.2%, P = 0.02). Of 383 recipients, 101 patients (26.4%) received grafts with WIT > 18 min, of whom there were 27 patients (26.7%) suffered from DGF (26.7% versus 16.7%, P = 0.03). Incidences of PNF and AR were also higher in the > 18 min group; however, no significant difference was found (3.1% versus 0.7% of PNF, P = 0.12; 13.5% versus 8.9% of AR, P = 0.31). Serum creatinine levels were recorded at different follow-up time points, and no significant difference was found in serum creatinine curves between the two groups (P = 0.08).

Graft and patient outcomes following kidney transplantation from DBCD and DBD
The median follow-up time for graft and recipient was 25 months (range 0.5–54 months, and 2–54 months, respectively). Graft survival in DBCD group was comparable to DBD group (P = 0.32; Fig. 2a). A similar analysis revealed no significant difference in recipient survival between the two groups (P = 0.86; Fig. 2b). One-year graft and recipient survivals were comparable between DBCD and DBD groups (97.4% versus 97.9%, P = 0.10 and 98.4% versus 98.6%, P = 1.0, respectively). In DBCD group, five patients had PNF, five severe bleeding and three renal allograft ruptures postoperatively and resected transplanted kidneys, whereas four patients had severe bleeding, two renal allograft rupture, one peri-renal abscess, and one severe AR from DBD. Regarding recipient survival, seven from DBCD group died from severe pneumonia or cardiovascular disease, and three from the DBD group died from severe pneumonia or myocardial infarction.

The cox regression regression analysis showed that no characteristics of recipients and donors in this study affected graft and recipient survivals following kidney transplantation from DBCD and DBD (P > 0.05).

Discussion
While brain death is recognized by the law in most Western countries, this concept is not readily accepted in Chinese society [19]. However, Chinese culture does recognize circulatory death, which formed the premise for the initiation of DCD [11]. The DCD guidelines were developed by the Chinese Society of Organ Transplantation to make recommendations that are ethically, legally, and medically acceptable in the practice of DCD [11]. However, a difference with the international common practice of deceased organ donation is the presence of an additional category III DBCD in the Chinese classification [10]. This new concept of donation is formulated based on the combination of the international practice of recognizing brain
death and circulatory death, which is different from the international common practice of Maastricht criteria of donation after cardiac death [11]. Inclusion of DBCD aims to boost the number of eligible organ donations while ensuring minimal ischemic injury of organs [10].

To our knowledge, this is the first multi-center cohort study to assess the outcomes of DBCD compared with DBD, showing that kidney transplantation from DBCD method confers comparable results with DBD. These findings suggest that DBCD is a viable graft accessibility option; thus may pave the way for a novel donation path for billions of people that face barriers to DBD.

In our study, graft and recipient survivals, as well as incidences of postoperative complications were equally comparable among DBCD and DBD. The 1-year graft survival of 97.4% in DBCD group was higher than previously reported values of 87% in DBD, and 85% in DCD [8, 9]. Previous studies reported recipient survival of 95% in DBD and DCD kidney transplantation at 1 year postoperatively, inferior to 98.4% in our DBCD group [20]. Incidence of DGF following DBD has been reported as around 24.9%, and DCD grafts have twice the risk of developing DGF, all of which were superior to 19.3% in DBCD [8, 9, 21, 22]. An increase in serum creatinine following transplantation is indicative of the presence of acute kidney injury (AKI) and DGF. Therefore, renal function recovery postoperatively can be understood through serum creatinine change curves. We compared serum creatinine curves postoperatively, and no significant difference was found, indicating similar renal function recovery between DBCD and DBD. Incidence of PNF in the DBCD group was equivalent to DBD in our study, which was also lower than reported value of 3% in DBD and DCD [9]. Previous studies have attributed higher incidence of PNF to the irreversible warm ischemic injury and perivascular edema of capillaries in DCD processes, which can result in high risk of PNF [21, 22]. However, the five grafts with PNF in DBCD group, only resulted because of severe glomerulosclerosis, confirmed through zero-time graft biopsy, and not through warm ischemia injury during organ procurement of DBCD. As for AR, there was a similar result among the two groups, which was also inferior to reported incidences of 24% in DBD and 16% in DCD [9].

The fundamental cause of comparable outcomes lies in controlled warm ischemia time during procurement of DBCD grafts. With regards to DCD, kidney is susceptible to prolonged warm ischemic injuries and severe anaerobic metabolism which results in increased risk of chronic allograft nephropathy and acute tubular necrosis. Prolonged warm ischemia time also causes further severe events related to ischemia and reperfusion injury (IRI) as well as AKI, all of which inevitably exert adverse effects on graft and recipient survival, and increase incidences of DGF and PNF [9, 22, 23]. However, DBCD in the case of planned protocols to withdraw mechanical support following brain death, can effectively limit warm ischemia time to an appropriate range. In our study, the average warm ischemia time of kidney from DBCD was limited to 16.2 ± 5.2 min, much lower than an average of 27 min through DCD [24]. Furthermore, we found higher incidences of DGF, PNF and AR in warm ischemia time of more than 18 min. We suppose that a controlled warm ischemia period of the DBCD process contributes to reducing IRI, and leads to better graft function recovery and survival. The controlled ischemia time also reduces production of chemokines or cytokines, and T cells into the graft, all of which can reduce AR [25, 26]. Additionally, lower incidences of DGF and AR in DBCD exert a positive effect on graft and recipient survival.

![Fig. 2 Kaplan-Meier survival estimates after renal transplantation in recipients of kidneys from DBCD and DBD. a Graft survival in the DBCD group was comparable to the DBD group (P = 0.32), HR 1.56, 95% CI 0.60–4.04. b A similar analysis revealed no significant difference in recipient survival between DBCD and DBD groups (P = 0.86), HR 1.13, 95% CI 0.28–4.50.](image-url)
A standard protocol defines the approval criteria for DBCD. Before declaration of brain death, an apnea test should be carried out to determine whether autonomous respiration exits. The test should be terminated if cardiac arrhythmia, decline of oxygen saturation and blood pressure are observed. In order to limit warm ischemic time, cardio-respiratory support should be withdrawn in the operating room after all necessary preparations have been completed, and the retrieval team and operating room staff should be ready in advance [11]. ATG is recommended as induction therapy in DBCD organ transplantation; in our study, ATG was used more frequently in recipients of DBCD donations and related with a lower incidence of DGF in comparison to basiliximab. A previous study has reported 1-year graft survival of 96.9% for ATG, and 75.9% for basiliximab [27]. Other studies also demonstrated improved trend in patient and graft survivals, as well as significantly lower rates of DGF, AR, and postoperative infections in ATG-induced DCD recipients [28-30]. Thus, these findings support the positive effect of ATG in decreasing DGF and AR in our study.

Through comparison of donor baseline characteristics, 59.8% of DBCD donors were identified to be older than 40 years, compared with 12.1% of DBD donors (P < 0.05), this may be attributed to the more conservative view held by older people in China regarding brain death, and the understanding of younger generation in DBD. Interestingly, a significantly higher proportion of DBCD donors died from cerebrovascular episodes. Age of a donor may have influenced this, as older people are potentially at a higher risk of developing cerebrovascular events.

Information about the long-term outcome of DBCD was not available in our study due to the limited time since which this novel donation pattern had been established. Additionally, more accurate measurement of warm ischemia time of DBCD should be ensured, which could account for the unexpected finding that PNF and AR were higher in the > 18 min group, although no significant difference was found. Warm ischemia time was reported no effect on graft outcome which may be attributed to insufficient samples size and inability to detect this effect [9, 31]. Thus, future, larger prospective studies are necessary to validate our findings, and standardized protocols for donor monitoring and data collection will improve the quality and completeness of data.

DBCD, a novel donation approach, provides an acceptable outcome in terms of both survival and postoperative complications, and should be regarded as equivalent to DBD. The benefits of DBCD largely arise from its controlled procurement process of grafts which reduces the risks of warm ischemia injury. The controlled processes of DBCD should therefore be strictly followed.

Conclusions
In conclusion, although DBD is currently the standard strategy for organ transplantation, our findings suggest that DBCD is a viable option to provide graft availability to renal transplant patients. In view of the large numbers of people universally who cannot accept DBD, DBCD can be considered a cultural and medical milestone that overcomes donation barriers.

Abbreviations
AKI: Acute kidney injury; AR: Acute rejection; ATG: Antithymocyte globulin; DBCD: Donation after brain death followed by circulatory death; DBD: Donation after brain death; DCD: Donation after circulatory death; DGF: Delayed graft function; HLA: Human leukocyte antigen; IRI: Ischemia and reperfusion injury; PNF: Primary non-function; PRA: Panel-reactive antibody

Funding
This study was supported by grants from National Natural Science Foundation of China (No. 81470978, 81279894); Major Program of Science and Technology Planning Project of Guangdong Province, China (No. 2015A020226005); Key Project of Natural Science Foundation of Guangdong Province, China (No. 2015A030311040); Leading Scientific, Technical and Innovation Talents of Guangdong Special Support Program (No. 510204006192). The funding organizations did not have any role in the study design, collection, analysis, or interpretation of data, in writing of the manuscript, or in the decision to submit the article for publication.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
QPS was involved in the study conception and design. QPS, HLZ, RHC, MZL, XFH, LQH, ZYH, NN, RMC, GW and FHM were involved in acquisition, analysis, and interpretation of data. QPS and HLZ were involved in drafting of the manuscript. QQS, LQH, ZYH and NN were involved in critical revision of the manuscript for important intellectual content. All the authors made the final approval of the version to be published.

Ethics approval and consent to participate
Study protocols were reviewed and approved by the Ethics Committees of The Third Affiliated Hospital of Sun Yat-sen University, The First Affiliated Hospital of Jilin University, The Second Affiliated Hospital of Guangzhou Traditional Chinese Medicine University, and The Third Affiliated Hospital of Guangzhou Medical University. Kidney procurement was conducted in accordance with the Declaration of Helsinki and Istanbul Declaration, and approved by the Human Organ Transplantation and Ethics Committee of each institution. The donation types were determined by donors’ families, who also signed consent forms that were approved by the Ethics Committees of each institution. All personal information collected were kept strictly confidential and used for research purposes only. Research team members were responsible for safekeeping the personal data.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Renal Transplantation, The Third Affiliated Hospital, Sun Yat-sen University, Kaichuang Road 2693, Huangpu District, Guangzhou 510530, People’s Republic of China. 2Department of Urology, The First Affiliated Hospital, Jilin University, Xinmin Road 71, Changchun 130000,
6. Shi BY, Chen LP. Regulation of organ transplantation in China: difficult exploration and slow advance. JAMA. 2011;306:434–40.

7. Reese PP, Boudville N, Garg AX. Living kidney donation: outcomes, ethics, and uncertainty. Lancet. 2015;385:2003–13.

8. Summers DM, Watson CJ, Pettigrew GJ, Johnson RJ, Collett D, Neuberger JM, Bradley JA. Kidney donation after circulatory death (DCD): state of the art. Kidney Int. 2015;88:241–9.

9. Summers DM, Johnson RJ, Allen J, Fuggle SV, Collett D, Watson CJ, Bradley JA. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. Lancet. 2010;376:1303–11.

10. Huang J, Millis JM, Mao Y, Millis MA, Sang X, Zhong S. Voluntary organ donation system adapted to Chinese cultural values and social reality. Liver Transpl. 2015;21:419–22.

11. Chinese Society of Organ Transplantation. Chinese Medical Association: national guidelines for donation after cardiac death in China. Hepatobiliary Pancreat Dis Int. 2013;12:234–8.

12. Huang J, Millis JM, Yao Y, Millis MA, Sang X, Zhong S. A pilot programme of organ donation after cardiac death in China. Lancet. 2012;379:862–3.

13. World Health Organization. Operational guidelines for ethics committees that review biomedical research. 2000. http://www.who.int/tdr/publications/documents/ethics.pdf?ua=1. Accessed 2 Dec 2016

14. Mallon DH, Summers DM, Bradley JA, Pettigrew GJ. Defining delayed graft function after renal transplantation: simplest is best. Transplantation. 2013;95:885–9.

15. Tjojimbana T, Fuchinoue S, Iwao K, Koyama I, Sannomiya A, Kato Y, Nannomou K, Kai K, Nakajima I, Toma H, Teraoka S. Improved outcomes of renal transplantation from cardiac death donors: a 30-year single center experience. Am J Transplant. 2007;7:609–17.

16. Haas M. The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transplant. 2016;16:1352–7.

17. Jochmans I, Darius T, Kuypers D, Monbaliu D, Goffin E, Mourad M, Ledin H, Weekers L, Peeters P, Randon C, Bosmans JL, Roeyen G, Abramowicz D, Hoang AG, De Paauw L, Rahmel A, Squifflet JP, Pirenne J. Kidney donation after circulatory death in a country with a high number of brain dead donors: 10-year experience in Belgium. Transpl Int. 2012;25:857–66.

18. Wu G, Gao X, Chen F, Tao X, Cai J, Guo J, Chen X, Tan J, Yang S. Chinese pediatric organ donation with scheduled cardiac arrest after brain death: a novel China classification beyond Maastricht. Transplant Proc. 2015;47:2836–40.

19. Sun Q, Gao X, Wang H, Xu D, Li X. A new era for organ transplantation in China. Lancet. 2014;383:1971–2.

20. Rao PS, Ojo A. The alphabet soup of kidney transplantation: SCD, DCD, ECD—fundamentals for the practicing nephrologist. Clin J Am Soc Nephrol. 2009;4:1827–31.

21. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of donor age and cold storage time on outcome in recipients of kidneys donated after circulatory death in the UK: a cohort study. Lancet. 2013;381:273–4.

22. Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant. 2011;11:2279–96.

23. Schrøppel B, Legendre C. Delayed kidney graft function: from mechanism to translation. Kidney Int. 2014;86:251–8.

24. Nagaraja P, Roberts GW, Stephens M, Horvath S, Fialova J, Chavez R, Asderakis A, Kapotas Z. Influence of delayed graft function and acute rejection on outcomes after kidney transplantation from donors after cardiac death. Transplantation. 2012;94:1218–23.

25. Daneman J, Daha MR, van Son WJ, Leuvenink HG, Ploeg RJ, Seelen MA. CROSSTALK between complement and toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant. 2011;11:660–9.

26. Eltzschig HK, Ecke T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17:1391–401.

27. Haldorson JB, Bakhvatsalarn R, Montenegro M, Dick A, Rayhill S, Perkins J, Reyes J. Differential rates of ischemic cholangiopathy and graft survival associated with induction therapy in DCD liver transplantation. Am J Transplant. 2015;15:251–8.

28. Popat R, Syed A, Pulatti C, Caccio R. Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants. Transplantation. 2014;97:1161–5.

29. Ulrich F, Niedzwiecki S, Pascher A, Kohler S, Weiss F, Sikatas P, Schumacher G, May G, Reinke P, Neuhaus P, Tullius SG, Pratschke J. Long-term outcome of ATG vs. basiliximab induction. Eur J Clin Investig. 2011;41:971–8.

30. Chen G, Gu J, Qiu J, Wang C, Fei J, Deng S, Li J, Huang G, Fu Q, Chen L. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. Exp Clin Transplant. 2013;11:310–4.

31. Scalea JR, Redfield RR, Arpali E, Leveson GE, Bennett RJ, Anderson ME, Kaufman DB, Fernandez LA, D’Alessandro AM, Foley DP, Mezrich JD. Does DCD donor time-to-death affect recipient outcomes? Implications of time-to-death at a high-volume Center in the United States. Am J Transplant. 2017;17:191–200.